Table 1.
Study | Drug | Mean Dose (mg/d) | Mean Dose (mg/kg/d) | Method of Dosing | N in Drug Group | N in Placebo Group | Mean Age | % Male |
---|---|---|---|---|---|---|---|---|
Conners[36] | MPH | 22 | .82 | Best | 20 | 20 | 12 | 95 |
Taylor[37] | MPH | DNP | DNP | Best | 37 | 37 | 9 | 100 |
Klorman[38] | MPH | 22.3 | .76 | Best | 44 | 44 | 9 | 84 |
Conners[12] | Bupropion | DNP | 6 | Best | 52 | 20 | 9 | 90 |
Schachar[39] | MPH | 31.9 | 1.2 | Best | 37 | 29 | 8 | 77 |
Manos[40] | MAS | 10.6 | DNP | Best | 42 | 42 | 10 | 79 |
Manos[40] | MPH | 19.5 | DNP | Best | 42 | 42 | 10 | 79 |
Zeiner[35] | MPH | DNP | .5 | Best | 36 | 36 | 9 | 100 |
Bostic[41] | Pemoline | 1.81 | 3 | Best | 21 | 21 | 14 | 86 |
Pliszka[42] | MAS | 12.5 | .31 | Best | 20 | 18 | 8 | DNP |
Pliszka[42] | MPH | 25.2 | .39 | Best | 20 | 18 | 8 | DNP |
James[33] | MAS | 10.3 | .32 | DNP | 35 | 35 | 9 | 60 |
James[33] | d-Amp | 10.3 | .32 | DNP | 35 | 35 | 9 | 60 |
James[33] | d-Amp ER | 10.3 | .32 | DNP | 35 | 35 | 9 | 60 |
Wolraich[7] | MPH | 29.5 | .9 | Best | 97 | 90 | 9 | 87 |
Wolraich[7] | MPH OROS | 34.3 | 1.1 | Best | 95 | 90 | 9 | 78 |
Michelson[20] | Atomoxetine | DNP | 1.8 | Fixed | 82 | 83 | 11 | 72 |
Michelson[43] | Atomoxetine | DNP | 1.3 | Best | 84 | 83 | 10 | 71 |
Biederman[44] | Atomoxetine | DNP | 2 | Best | 31 | 21 | 10 | 0 |
Biederman[8] | MAS XR | 30 | DNP | Fixed | 120 | 203 | 9 | 80 |
Greenhill[6] | MPH MR | 40.7 | 1.28 | Best | 155 | 159 | 9 | 83 |
Spencer[45] | Atomoxetine | 90 | 2 | Best | 49 | 47 | 10 | 81 |
Spencer[45] | Atomoxetine | 90 | 2 | Best | 53 | 45 | 10 | 81 |
Biederman[46] | MPH-LA | DNP | DNP | Best | 63 | 71 | 9 | 77 |
Wigal[47] | MPH | 32.14 | DNP | Best | 41 | 41 | 10 | 88 |
Wigal[47] | d-MPH | 18.25 | DNP | Best | 42 | 41 | 10 | 88 |
Swanson[48] | Modafinil | 395.3 | DNP | Fixed | 120 | 63 | 10 | 74 |
Biederman[49] | Modafinil | 382.5 | DNP | Fixed | 120 | 63 | 10 | 74 |
Findling[50] | MPH OROS | 54 | DNP | Best | 89 | 85 | 9 | 70 |
Findling[50] | MTS | 27 | DNP | Best | 96 | 85 | 9 | 66 |
Pelham[51] | MTS | 31.6 | DNP | Fixed | DNP | DNP | 10 | 87 |
Greenhill[52] | Modafinil | 297.5 | DNP | Best | 128 | 66 | 10 | 73 |
Kelsey[53] | Atomoxetine | DNP | 1.3 | Best | 126 | 60 | 10 | 71 |
Wilens[34] | MPH OROS | 53.6 | DNP | Best | 87 | 90 | 15 | 80 |
Spencer[54]a | MAS-XR | 40 | DNP | Fixed | 27 | 24 | 14 | 64 |
Spencer[54]b | MAS-XR | 40 | DNP | Fixed | 26 | 28 | 14 | 64 |
Findling[55] | MPH | 30 | DNP | Best | 120 | 39 | 10 | 79 |
Findling[55] | MPH-MR | 30 | DNP | Best | 120 | 39 | 10 | 81 |
Note: Studies are listed more than once if they studied more than 1 drug or presented more than 1 independent trial of the same drug; MPH = methylphenidate; DNP = data not provided; MAS = mixed amphetamine salts; d-Amp = dextroamphetamine; d-Amp ER = dextroamphetamine extended release; MAS XR = mixed amphetamine salts-extended release; d-MPH = dexmethylphenidate; MPH MR = methylphenidate modified release; MPH-LA = methylphenidate long acting; MPH OROS = methylphenidate using osmotic-release oral system technology; MTS = methylphenidate transdermal system.
Severe ADHD group;
Mild ADHD Group (demographics not given separately for each group)